Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial

Conclusions
In patients with adefovir-resistant HBV and multiple-drug failure, TDF monotherapy provided a virological response comparable to that of TDF and ETV combination therapy, and was safe up to 96 weeks.

Trial registration number
NCT01639066.

Source: Gut - May 9, 2016 Category: Gastroenterology Authors: Lim, Y.-S., Yoo, B. C., Byun, K. S., Kwon, S. Y., Kim, Y. J., An, J., Lee, H. C., Lee, Y. S. Tags: Hepatology Source Type: research